0000899243-23-008752.txt : 20230316 0000899243-23-008752.hdr.sgml : 20230316 20230316175237 ACCESSION NUMBER: 0000899243-23-008752 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230314 FILED AS OF DATE: 20230316 DATE AS OF CHANGE: 20230316 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: KIRSKE DAVID CENTRAL INDEX KEY: 0001276750 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-28386 FILM NUMBER: 23740034 MAIL ADDRESS: STREET 1: C/O CTI BIOPHARMA CORP. STREET 2: 3101 WESTERN AVE., SUITE 600 CITY: SEATTLE STATE: WA ZIP: 98121 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: CTI BIOPHARMA CORP CENTRAL INDEX KEY: 0000891293 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 911533912 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 3101 WESTERN AVENUE STREET 2: SUITE 800 CITY: SEATTLE STATE: WA ZIP: 98121 BUSINESS PHONE: 2062827100 MAIL ADDRESS: STREET 1: 3101 WESTERN AVENUE STREET 2: SUITE 800 CITY: SEATTLE STATE: WA ZIP: 98121 FORMER COMPANY: FORMER CONFORMED NAME: CELL THERAPEUTICS INC DATE OF NAME CHANGE: 19960321 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2023-03-14 0 0000891293 CTI BIOPHARMA CORP CTIC 0001276750 KIRSKE DAVID 3101 WESTERN AVENUE, SUITE 800 SEATTLE WA 98121 0 1 0 0 EVP, Chief Financial Officer Stock Option (right to buy) 4.55 2023-03-14 4 A 0 200000 0.00 A 2033-03-14 Common Stock 200000 200000 D The stock option will vest in six equal semi-annual installments over a three-year period, subject to continued employment with the Company through the applicable vesting dates. /s/ David Kirske 2023-03-16